A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...
Intravesical sequential BCG and electromotive mitomycin versus BCG alone in high risk non-muscle invasive bladder cancer. Results of a phase II study of pralatrexate in patients with ...
Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer. Arlene Siefker-Radtke, MD: Another interesting trial presented at ...
Noninvasive treatment options for NGB dysfunction include intermittent catheterization, Crede and Valsalva, indwelling catheterization, lifestyle changes/behavioral modification, and oral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results